Lahore: Highnoon Laboratories Limited has fulfilled its regulatory obligations by releasing the Mandatory Shariah Disclosure for the financial year ending December 31, 2025. This disclosure is part of the compliance with PSX Notice No. PSX/N-435, issued on April 17, 2026, under Clause No. 5.6.9A of the Pakistan Stock Exchange Regulations.

The disclosure, which has been incorporated into the company’s Annual Report for 2025, outlines the financial activities categorized by their compliance with Shariah law. According to information available from the Pakistan Stock Exchange (PSX), the report details both Shariah-compliant and non-compliant financial activities of the company.

In the unconsolidated financial statements for 2025, Highnoon Laboratories reported Shariah-compliant revenue from contracts totaling approximately 25.79 billion rupees, a significant move from the 23.20 billion rupees reported the previous year. The report also highlights Shariah-compliant bank balances amounting to 394.90 million rupees.

The designated market category under which this report falls is pharmaceuticals, and the disclosure further details Shariah-compliant profits on deposit accounts, short-term investments, and other incomes. Specific figures include a Shariah-compliant short-term investment of 598.17 million rupees and a Shariah-compliant bank deposit of 39.35 million rupees.

The report also includes non-Shariah-compliant financial activities, such as accrued markup and finance costs paid. These non-compliant activities are detailed separately, with a noted finance cost of 19.65 million rupees for the period.

Highnoon Laboratories Limited has ensured that the stock market participants, particularly the TRE Certificate Holders, are informed of these disclosures as per the regulatory requirements.